| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TVTX | Common Stock | Award | $0 | +3,300 | +5.5% | $0.000000 | 62,988 | 31 Aug 2023 | Direct | F1, F2 |
| transaction | TVTX | Common Stock | Sale | $26,699 | -1,815 | -2.9% | $14.71 | 61,173 | 05 Sep 2023 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 5,000 shares of the Issuer's common stock. On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio. |
| F2 | Includes 477 shares of the Issuer's common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program. |
| F3 | The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. |